Charles Schwab Investment Management Inc. Increases Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Charles Schwab Investment Management Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 17.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,274,003 shares of the company’s stock after acquiring an additional 333,323 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Recursion Pharmaceuticals were worth $15,372,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares in the last quarter. FMR LLC lifted its position in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after buying an additional 170,810 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock valued at $14,108,000 after buying an additional 43,078 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock valued at $7,751,000 after purchasing an additional 67,464 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the subject of several recent research reports. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Finally, KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Stock Down 1.5 %

Shares of RXRX opened at $6.48 on Friday. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $12.36. The company has a market capitalization of $2.60 billion, a PE ratio of -4.24 and a beta of 0.85. The stock has a fifty day simple moving average of $7.47 and a two-hundred day simple moving average of $7.00. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period last year, the business earned ($0.42) earnings per share. The firm’s revenue was down 57.8% compared to the same quarter last year. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.